8-K: Century Therapeutics Prioritizes Pipeline, Extends Cash Runway into Q4 2026

Century Therapeutics is focusing its pipeline on four key programs and expects its cash to last into the fourth quarter of 2026.

Summary

• Century Therapeutics reported its full year 2024 financial results and provided a business update.
• The company is re-prioritizing its preclinical pipeline to focus on four potentially transformative programs, led by CNTY-308 for B-cell mediated autoimmune diseases and malignancies.
• CNTY-101 will have a new concentrated clinical focus based on its unique profile with transformational potential in autoimmune disease, with data anticipated in 2025.
• The company estimates its cash runway has been extended into the fourth quarter of 2026.
• The company discontinued the Phase 1 ELiPSE-1 trial early.
• The first patient in the CALiPSO-1 Phase 1 trial in autoimmune diseases is enrolled and scheduled for dosing in March 2025.
• The CARAMEL IIT is expected to commence in mid-2025 following CTA approval.
• Cash, cash equivalents, and marketable securities were $220.1 million as of December 31, 2024, compared to $261.8 million as of December 31, 2023.
• Net cash used in operations was $110.1 million for the year ended December 31, 2024, compared to $88.3 million for the year ended December 31, 2023.
• Collaboration revenue was $6.6 million.
• Research and Development (R&D) expenses were $107.2 million for the year ended December 31, 2024.
• General and Administrative (G&A) expenses were $33.2 million for the year ended December 31, 2024.
• Net loss was $126.6 million for the year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The company is focusing its pipeline and extending its cash runway, which is positive. However, the discontinuation of a clinical trial and increased net cash used in operations are concerning.

Positives

• The company is focusing on potentially transformative programs.
• The company has a strong cash position of $220.1 million as of December 31, 2024.
• The company estimates its cash, cash equivalents, and investments will support operations into the fourth quarter of 2026.
• The first patient in the CALiPSO-1 Phase 1 trial in autoimmune diseases is enrolled and scheduled for dosing in March 2025.
• The CARAMEL IIT is expected to commence in mid-2025 following CTA approval.

Negatives

• The company discontinued the Phase 1 ELiPSE-1 trial early.
• Net cash used in operations increased to $110.1 million for the year ended December 31, 2024, compared to $88.3 million for the year ended December 31, 2023.
• The company reported a net loss of $126.6 million for the year ended December 31, 2024.

Risks

• The company's ability to successfully advance its product candidates through development activities, preclinical studies, and clinical trials is uncertain.
• The company is dependent on the success of its lead product candidate, CNTY-101.
• The company's ability to meet development milestones on anticipated timelines is not guaranteed.
• The company relies on key collaborative relationships for manufacturing and development.
• The timing, scope, and likelihood of regulatory filings and approvals are uncertain.

Future Outlook

The company is focused on advancing its prioritized programs and expects to achieve meaningful milestones and drive value for all stakeholders. The company estimates its cash, cash equivalents, and investments will support operations into the fourth quarter of 2026.

Management Comments

• We ended the year with a strong cash position, which we will leverage to achieve meaningful milestones and drive value for all stakeholders as we take the company forward in a new direction, said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.
• We believe CNTY-101 is well-positioned to potentially impact the standard of care meaningfully in B-cell-mediated autoimmune diseases.
• We believe these exciting programs unlock an opportunity to replace current therapies and expand application of cell therapy to areas with serious medical need, starting with what we believe to be our unique ab CD4+/CD8+ CAR-T cells combined with our most advanced Allo-Evasion 5.0 technology , said Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics.

Industry Context

Century Therapeutics is operating in the competitive cell therapy space, focusing on iPSC-derived cell therapies for cancer and autoimmune diseases. The company's Allo-Evasion technology aims to differentiate it from other allogeneic cell therapy approaches by enabling repeat dosing and potentially improving efficacy and safety.

Comparison to Industry Standards

• The company is aiming for comparable or better performance to approved autologous CAR-T therapies with its CNTY-308 and CNTY-341 programs in B-cell-mediated diseases.
• The company's approach to allogeneic cell therapy using iPSCs and Allo-Evasion technology is intended to address the limitations of autologous CAR-T therapies, such as manufacturing challenges and safety concerns.
• The company's focus on autoimmune diseases with CNTY-101 aligns with the growing interest in cell therapies for these indications, as demonstrated by emerging data for allogeneic cell therapies from other companies.

Stakeholder Impact

• Shareholders: The pipeline re-prioritization and cash runway extension could impact shareholder value.
• Patients: The focus on autoimmune diseases and the development of new therapies could benefit patients with unmet medical needs.
• Employees: The pipeline re-prioritization may lead to changes in staffing and resource allocation.

Next Steps

• Advance CNTY-308 toward product candidate selection.
• Initiate IND-enabling studies with CNTY-308 in mid-2025.
• Continue expansion of Phase 1 CALiPSO-1 trial in the US and EU.
• Commence CARAMEL IIT in mid-2025 following CTA approval.
• Present further data on ELiPSE-1 in 2025.
• Host a live webcast on April 22nd to discuss the prioritized programs.

Key Dates

Keywords

Century Therapeutics, iPSC, cell therapy, autoimmune disease, cancer, CNTY-101, CNTY-308, clinical trial, pipeline, financial results